This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

This study has been completed.
Information provided by:
Poitiers University Hospital Identifier:
First received: September 13, 2005
Last updated: August 28, 2012
Last verified: September 2005
The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase who are in relapse after stem cell transplantation.

Condition Intervention Phase
Chronic Myeloid Leukemia Drug: Imatinib mesylate Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Poitiers University Hospital:

Primary Outcome Measures:
  • - to assess the tolerability of Imatinib given at a daily dose of 400mg
  • - to evaluate the hematologic, cytogenetic and molecular responses at various check points.

Secondary Outcome Measures:
  • - to assess donor/recipient chimerism during Imatinib therapy
  • - to evaluate the survival

Estimated Enrollment: 30
Study Start Date: May 2002
Estimated Study Completion Date: July 2007
Detailed Description:

Patients will received Imatinib at a dose of 400mg daily. The tolerability of Imatinib given at a daily dose of 400mg will be assessed. The hematologic, cytogenetic and molecular responses will be evaluated at various check points.

Donor/recipient chimerism during Imatinib therapy will be assessed. Survival will be estimated.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CML Ph+ (assessed by cytogenetic or FISH)
  • Age ≥ 18 year at inclusion
  • PS grade 0 to 2 (ECOG)
  • previous allogeneic stem cell transplantation
  • molecular, cytogenetic or haematological relapse in chronic phase after transplantation
  • Immune therapy for graft versus host disease stopped within 2 months from inclusion
  • Adequate and organ function, defined as the following: total bilirubin <3x uln, sgpt <3x uln, creatinine <2x uln.
  • informed consent sign up

Exclusion Criteria:

  • Age less than 18 y
  • accelerated or blastic phase
  • previous therapy with imatinib
  • active malignancy other than CML or non-melanoma cancer of the skin
  • current treatment with another investigational agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00219726

University Hospital
Poitiers, France, 86021
Sponsors and Collaborators
Poitiers University Hospital
Study Chair: François GUILHOT, MD Department of Oncology Hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE
Principal Investigator: Agnès DEVERGIE, MD University Hospital "Saint-Louis" - Department of Hematology and Oncology - 75475 PARIS Cedex 10 (FRANCE)
  More Information

Additional Information: Identifier: NCT00219726     History of Changes
Other Study ID Numbers: 020947
Study First Received: September 13, 2005
Last Updated: August 28, 2012

Keywords provided by Poitiers University Hospital:
Imatinib mesylate
Stem cell transplantation

Additional relevant MeSH terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Leukemia, Myeloid
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017